Document is current
Any future updates will be listed below
-
Authors
O’Brien, John T.
Chouliaras, Leonidas
Sultana, Janet
Taylor, John-Paul
Ballard, Clive
,
Aarsland, Dag
Blanc, Frederic
Boeve, Bradley
Brooks, David J.
Chaudhuri, K. Ray
Cummings, Jeffrey
Feldman, Howard H.
Flicker, Leon
Galvin, James E.
Grosset, Donald G.
Ikeda, Manabu
Kohlhaas, Susan
Lawlor, Brian
Lemstra, Afina W.
Leroi, Iracema
Londos, Elisabet
Leverenz, James B.
Lewis, Simon
McKeith, Ian
Mills, Roger
Oakley, Richard
Richardson, Jill
Sabbagh, Marwan
Skidmore, John
Svennigsson, Per
Tiraboschi, Pietro
Weintraub, Daniel
Walker, Zuzana
Watson, Rosie
Weil, Rimona S.
Williams-Gray, Caroline H.
Yarnall, Alison
- License Information
-
More Information
Article History
Received: 5 July 2022
Accepted: 17 October 2022
First Online: 11 November 2022
Declarations
:
: Not applicable.
: Not applicable.
: JOB has acted as a consultant for TauRx, Eisai, Novo Nordisk, Biogen and GE Healthcare and received grant support from Avid/ Lilly, MSD and Alliance Medical. J-PT has acted as a consultant for Sosei Heptares, Kyoma-Kirin and received speaker fees from GE Healthcare.FBPS has acted as a consultant for BiogenAbbVie and received speaker Lundbeck. DG has received grant funding from Parkinson’s UK, honoraria from BIAL Pharma, AbbVie, Britannia Pharmaceuticals and consultancy fees from Roche and Biogen; FB is or was the national coordinator for France of clinical trials on DLB (Headway-DLB, Axovant; Delphia, Eisai) and AD (Graduate and PostGraduate, Roche).
